US judge rules Merck won’t face “punitive damages” in first Fosamax caseBMJ 2009; 339 doi: https://doi.org/10.1136/bmj.b3225 (Published 06 August 2009) Cite this as: BMJ 2009;339:b3225
- Ray Moynihan
A district court judge in the United States has ruled that the drug maker Merck will not face the risk of “punitive damages” in the first case to be tried involving its widely prescribed osteoporosis drug, Fosamax (alendronate or alendronic acid).
The trial was scheduled to open on Tuesday in New York before Judge John Keenan, and the first case involves Shirley Boles, a woman from Florida who first took the drug in 1997.
Ms Boles is part …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial